Atrimon is indicated for the short-term symptomatic management of insomnia. This includes addressing core symptoms such as difficulty initiating sleep and the challenge of staying asleep. This medication is applied across therapeutic domains where additional symptomatic support is needed, particularly when sleep difficulties become temporarily overwhelming.

Atrimon is commonly used to help with the symptoms of sleep initiation insomnia (delayed sleep onset) and sleep maintenance insomnia (frequent nocturnal awakenings), offering symptomatic relief that helps patients cope more steadily.

“This short-term approach is primarily relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain.”

Targeted Symptom Relief

Atrimon is commonly used to help with the challenge of delayed sleep onset, a core symptom of sleep initiation insomnia. It is applied in clinical settings that involve acute or disruptive sleep patterns, providing support that helps ease the symptom load. The main therapeutic benefit is that the medication assists with the symptomatic challenge of falling asleep, which contributes to improved comfort during periods of heightened symptoms. It is also relevant in contexts where sleep continuity is affected, assisting patients who face difficulty staying asleep throughout the night. This assists with managing symptoms that interfere with daily comfort.

Quick Fact: Supports Easing Delayed Sleep Onset Challenge (Sleep Initiation)

Regulatory References

1. NIH DailyMed database

Official Eligibility and Population Restrictions

Eligibility to use Atrimon (Zolpidem Tartrate) is strictly defined by government regulatory documents, outlining populations permitted to use the medicine and those who are formally prohibited or restricted.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated in patients with a known hypersensitivity to zolpidem, a history of Complex Sleep Behaviors (such as sleep-driving) following zolpidem intake, severe hepatic insufficiency (severe liver problems), sleep apnoea syndrome, and myasthenia gravis.

Age and Physiological Eligibility

Atrimon is indicated for the short-term treatment of insomnia in adults (typically 18 years and older). Use is not recommended in children and adolescents under 18 years, as safety and effectiveness have not been established in the pediatric population. In older adults (geriatric patients), use is permitted but subject to restricted use; the official label mandates a lower starting dose.

Reproductive and Functional Restrictions

Use is not recommended during pregnancy, especially in the third trimester, due to potential risks to the newborn. It is also not recommended for breastfeeding mothers. Patients with mild-to-moderate hepatic impairment and older adults require restricted use due to altered drug clearance or increased sensitivity.

Interactions with other medicines and products

Atrimon belongs to a class of medicines that act as a Central Nervous System (CNS) depressant. As a result, its most significant and clinically relevant interactions occur when it is used concomitantly with other substances that also depress CNS function, leading to potential additive effects.

Product Category	Interaction Severity Classification
CNS Depressants (e.g., Opioids, other Hypnotics/Sedatives, Anxiolytics, Antipsychotics, Antidepressants, Alcohol)	Major (Highly clinically significant, generally avoid)
CYP 3A4 Inhibitors (e.g., certain azole antifungals)	Moderate (Use with caution)
CYP 3A4 Inducers (e.g., Rifampicin)	Moderate (Use with caution)

Official Interaction Statements

• Concomitant use with alcohol or other CNS depressants is strictly restricted due to the high risk of compounding the depressant effects. This combination may result in profound sedation, clinically significant respiratory depression, coma, and death.
• The combination with strong CYP3A4 inhibitors may increase the plasma concentration of Atrimon, which enhances its sedative effects and requires dose modification. Conversely, co-administration with strong CYP3A4 inducers may decrease drug exposure, potentially reducing the hypnotic's efficacy.
• Monitoring for signs of excessive sleepiness, dizziness, and respiratory compromise is essential if co-administration with any other CNS depressant agent is deemed necessary.

This interaction profile is primarily defined by the pharmacodynamic interaction of additive CNS depression and a secondary pharmacokinetic interaction involving the cytochrome P450 enzyme system, specifically CYP3A4, which dictates how the medicine is processed by the body. This structure requires careful assessment of all concurrent medications to prevent serious adverse events.

Selective Modulation of CNS Inhibitory Circuits

Atrimon functions as a Positive Allosteric Modulator (PAM) at the central mathbfGABA Ahspace0.2emreceptor, the brain's primary site for inhibitory signaling. The molecule displays a high, preferential affinity for receptor complexes that contain the mathbfalpha1hspace0.2emsubunit. These alpha1-containing receptors are abundant in the brain regions that govern arousal. This selective binding enhances the effect of the inhibitory neurotransmitter mathbfGABA, leading to a functional reduction of high-frequency action potential firing in circuits associated with arousal.

Amplification of Neuronal Quieting Cascade

The binding of Atrimon stabilizes the GABA A receptor in a conformation that increases the frequency of its chloride ion (mathbfCl^-) channel opening. This substantial influx of negative chloride ions causes the nerve cell membrane to become hyperpolarized—a state of significant cellular inhibition. This molecular cascade reduces the excitability of the targeted neurons, resulting in the physiological consequence of mathbfsedation and mathbfhypnosis.

Functional Limits of Receptor-Driven Action

The drug's mechanism is subject to biological constraints; chronic, repeated modulation of the GABA A receptor can trigger adaptive changes like receptor desensitization or down-regulation. This compensatory effort by the central nervous system limits the drug's long-term efficacy, leading to functional tolerance.

Official Administration Guidelines for Atrimon (Zolpidem Tartrate)

Atrimon is used according to strict, short-term protocols and must be taken only once per night. The medicine is available in various forms for Oral or Sublingual administration.

---

Dosage and Schedule

Population / Form	Initial Labeled Dose (Once Nightly)	Maximum Labeled Dose	Duration of Use
Adults (IR¹ Forms)	5 mg (women) or 5-10 mg (men)	10 mg	Shortest duration possible, generally less than 4 weeks (including tapering)
Adults (ER² Forms)	6.25 mg (women) or 6.25-12.5 mg (men)	12.5 mg	Shortest duration possible
Elderly/Hepatic Impairment	5 mg (IR) or 6.25 mg (ER)	5 mg (IR) or 6.25 mg (ER)	Shortest duration possible

¹ IR = Immediate-Release; ² ER = Extended-Release.

---

Administration Conditions and Constraints

The medicine is taken immediately before bedtime. The total daily dose must not be re-administered during the same night.

Condition	Instruction
Timing with Meals	Should not be taken with or immediately after a meal for best use.
Sleep Commitment	Requires a commitment to at least 7 to 8 hours of sleep after taking the dose.
Preparation	Extended-Release forms must be swallowed whole and should not be crushed, divided, or chewed. Sublingual tablets must be held under the tongue until fully disintegrated.
Pediatric Use	Not recommended for children and adolescents under 18 years of age due to lack of established safety and effectiveness data.

This structured approach defines the required dosing and timing, ensuring the use of Atrimon is strictly aligned with established protocols.

Research Evidence / Overview of studies for Atrimon (HYPNOTIC)

---

Research Landscape for Short-Term Insomnia Management

The primary evidence available for Atrimon is based on short-term randomized controlled trials (RCTs). This type of research was applied in studies examining patient-reported experiences and how symptoms change over a defined, short time period. Clinical research examined Atrimon in individuals presenting with difficulty falling asleep (sleep initiation) and difficulty staying asleep (sleep maintenance).

Researchers examined various outcomes related to sleep. Some studies relied on objective measures, where participants were monitored in a sleep lab using equipment like polysomnography (PSG). Other research applied in studies examining patient-reported experiences, asking individuals to self-report sleep quality and awakening frequency. The evidence base also includes systematic reviews and meta-analyses which summarize the data collected across multiple trials. Studies reported measurements where the observed sleep outcomes for Atrimon groups were compared against the outcomes reported by the placebo groups. However, evidence contributes to understanding symptom patterns primarily over short periods, as most of this foundational research focused on temporary, acute changes.

---

How Studies Evaluated Sleep Initiation and Maintenance

In studies focused on falling asleep (sleep initiation), researchers monitored both the time to sleep onset as measured by lab equipment and the time patients reported it took them to fall asleep. These studies were observed over defined time intervals, typically less than one month. For sleep maintenance, research examined outcomes related to nocturnal awakening frequency and the total duration of sleep. Studies reported how symptoms evolved in the observed populations, and these outcomes reflected areas of daily functioning relevant to insufficient rest. Regulatory authorities summarizing this evidence noted that the outcomes reported were short-term and specific to the populations studied in the trials.

---

Evidence in Specific Adult and Older Adult Populations

Atrimon was evaluated in the general adult population with insomnia, typically aged 18 to 64. The results apply only to the populations studied under the specific conditions of the trials. Research specifically examined how symptoms were measured in older adults (aged 60 and above). Data show patterns related to outcomes observed in older adults that sometimes differed from the general adult population, which led to specific regulatory review of the findings. Additionally, some research has explored the evidence derived from settings with varying symptom burdens, such as patients with chronic primary insomnia.

---

Long-Term Research and Follow-up Durations

The primary evidence available for Atrimon covers studies ranging from one week up to about five weeks. While evidence is limited, some studies focusing on specific formulations or long-term management protocols have monitored patients over extended periods, with some research extending up to six to eight months of observation. This extended research provides insight into short-term changes. However, the certainty remains low regarding the consistency of outcomes beyond the trial's duration.

---

The Role of Regulatory Reviews and Evidence Gaps

Research provides context about what has been observed and where uncertainty remains regarding Atrimon. The data for certain groups remain insufficient, and the longest follow-up durations were limited across the most robust studies. There is limited information for long-term outcomes, meaning that the sustained impact on sleep and daily functioning over many months or years is not fully established. Studies have observed patterns related to next-day impairment, such as decreased alertness or cognitive function. Data are still emerging in this area, and certainty remains low. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the trials.

Key Studies & References Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation (NIHR HTA)

Common questions about Atrimon (HYPNOTIC) (FAQ)

---

Q: How quickly does Atrimon start working after taking it?

Official product information states that the immediate-release form of Atrimon is designed for rapid action. The medication works quickly to reduce the time it takes to fall asleep, with the onset typically occurring within 30 minutes of taking the dose. This rapid effect is a reason why the product labeling specifies the timing of administration.

---

Q: What is the typical length of time Atrimon stays in the body?

According to the clinical pharmacology data, Atrimon is eliminated from the body relatively quickly. The elimination half-life of the active ingredient (Zolpidem) is approximately 2.5 to 2.6 hours in healthy adults. This time period may be longer in specific populations, such as older adults or people with liver impairment.

---

Q: Can taking Atrimon affect the quality of natural sleep?

Studies reviewed by regulatory bodies indicate that Atrimon helps manage the core symptoms of insomnia. The evidence shows that it can help increase the total duration of sleep and decrease the frequency of awakenings during the night. The medicine is intended to facilitate a sleep state that aligns with regulatory goals.

---

Q: Does Atrimon interact with commonly used over-the-counter pain relievers?

Official documents highlight that Atrimon primarily interacts with other central nervous system (CNS) depressants, which can lead to excessive drowsiness or sedation. While specific interactions with all over-the-counter (OTC) products are not listed, official documentation notes that information regarding all co-administered drugs and products can be reviewed with a healthcare provider.

---

Q: Is Atrimon safe to use if I have kidney issues?

The regulatory data on how the body processes the medication suggests that no specific dose adjustment is typically needed for patients with compromised kidney function. However, the official guidance indicates that caution is warranted in people with severe kidney disease.

---

Q: Can Atrimon be taken by people who have anxiety in addition to sleep problems?

The official warnings emphasize that persistent sleep difficulties may be a symptom of an underlying physical or psychiatric disorder. Regulatory information advises that a healthcare provider carefully evaluate the patient for underlying conditions, as sleep disturbances may be symptoms of a separate psychiatric disorder.

---

Q: Is it normal to have unusual dreams when taking Atrimon?

The official adverse reactions tables included in regulatory documents list Abnormal dreams as a reported side effect that occurred during clinical trials.

---

Q: What happens if I forget to take my Atrimon dose at the usual time?

Regulatory rules strictly state that the total dose is not to be re-administered during the same night. If a dose is missed and the user has less than the required time available for sleep, official patient information generally describes skipping the missed dose and waiting for the next scheduled time if the required sleep commitment cannot be met.

---

Q: How does Atrimon compare to other prescription sleep aids in general terms?

Atrimon is formally classified as a Z-drug, which is a type of sedative-hypnotic medicine. This classification confirms that Atrimon is chemically different from the traditional benzodiazepine class of sleep medicines. It works by selectively targeting a specific subunit (alpha1) of the brain's GABA A receptor system.

---

Q: Can Atrimon cause rebound sleeplessness when a person stops taking it?

Official warnings note that stopping the drug abruptly, or a rapid dose reduction, may lead to withdrawal symptoms. This discontinuation can result in a temporary worsening of sleep difficulties, which is the effect commonly referred to as rebound sleeplessness.

---

Q: Is Atrimon used to treat all types of sleep difficulties?

Atrimon is officially indicated only for the short-term treatment of insomnia. Specifically, it is used to manage difficulties with sleep initiation (falling asleep), and certain formulations may be indicated for sleep maintenance (staying asleep). The drug is not indicated for other specific sleep disorders.

---

Q: Is it possible to take Atrimon and still wake up feeling refreshed?

Official product information emphasizes avoiding known negative outcomes, such as next-day impairment, which includes symptoms like grogginess or decreased alertness. The labeling includes a requirement for a minimum time commitment to sleep after the medicine is administered to mitigate the risk of impairment.

---

Q: What are the official sources that contain information about Atrimon?

Factual and authoritative information about Atrimon is published in public documents released by government health authorities. Key sources include the U.S. Food and Drug Administration (FDA)-approved drug labels, DailyMed, and consumer information provided by the National Institutes of Health (NIH) MedlinePlus.

---

Q: Is Atrimon ever used for jet lag or shift work sleep disorder?

The medicine is strictly indicated by regulatory agencies only for the short-term treatment of insomnia in adults. Its use for conditions like jet lag or sleep issues related to shift work is not included in the official labeling.

---

Q: Can Atrimon cause changes in appetite or weight?

Clinical trials reviewed by regulatory bodies have reported some changes related to appetite. Appetite disorder and a specific type of behavioral change called binge eating are listed among the reported adverse reactions in the official safety tables.

---

Q: What are some of the less common but important safety warnings for Atrimon?

The full safety tables in regulatory documents list adverse events that occurred at various frequencies, including those that are less common (below 1% incidence). The comprehensive warnings and side effects section of the product labeling contains the full list of reported adverse events.

---

Q: Is it safe to take Atrimon if I have a history of depression or mental health issues?

Official warnings state that the drug may be associated with the worsening of depression or the emergence of new behaviors, including suicidal thinking. The regulatory guidance indicates the need for careful evaluation of patients with a history of depression by a healthcare provider.

---

Q: Can Atrimon cause any effects on mood or behavior?

The safety warnings include reports of abnormal thinking and behavioral changes. These changes can include agitation, bizarre behavior, decreased inhibition, and a reported worsening of existing anxiety or depression. These are considered serious adverse reactions.

---

Q: Does Atrimon affect blood pressure or heart rate?

Regulatory documents indicate that the medicine can have effects on cardiovascular markers. Increased blood pressure is listed as a reported adverse reaction in clinical studies. Additionally, some regulatory research has observed a decrease in average heart rate during the sleep period.

---

Q: What official documents describe the drug's purpose?

The approved purpose and use conditions of the medicine are formally defined in key regulatory documents. These include the FDA-approved drug label (such as those found on DailyMed), the Summary of Product Characteristics (SmPC) used in Europe, and the official patient information leaflets published by the regulatory authority.

How to Store and Dispose of Atrimon (HYPNOTIC)?

Official regulatory information defines mandatory conditions for storing and disposing of this controlled substance to ensure stability and public safety.

Storage & Disposal Scope	Official Regulatory Statement
Labeled Storage Temperature Requirements	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Permitted temperature excursions are 15 C to 30 C (59 F to 86 F).
Light/Moisture Protection Requirements	The product must be protected from moisture and humidity, and kept away from excessive heat and direct light.
Packaging-Related Storage Rules	Keep the medication in its original container and ensure the container is tightly closed when not in use.
Child-Protection Storage Requirements	It is a mandatory rule to keep Atrimon out of the sight and reach of children due to safety concerns.
Official Disposal Instructions	Unused or expired medication must be disposed of via authorized methods, such as a pharmacy take-back program or a disposal kiosk. Do not discard the product in the wastewater or household trash.

Connection to the overall storage/disposal profile Regulatory documents stipulate that this medication must be kept within a strict temperature range and protected from moisture to prevent degradation. The labeling requires the product to remain securely stored in its original, closed container. As a federally controlled substance, disposal must follow authorized methods, which specifically prohibits flushing or throwing the product into general waste streams.